ORLANDO, FL USA (UroToday.com) - Bilateral multifocal oncocytoma (BMO) is often confused with Birt-Hogg-Dube because of the similarity with kidney lesions in radiological imaging. Daniel Su and colleagues presented on the clinical characteristics, diagnosis, management, and outcome of BMO patients at the National Cancer Institute.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The authors identified 29 patients from 1999 to 2013 for this retrospective review. Patients were followed with serial imaging and mostly managed with renal biopsy and active surveillance.
Patients with BMO had mean tumor diameter of 4.4cm and eGFR of 46ml/min. Average growth rate was 0.20cm per year in this population. The mean renal function decreased after 52 months of median follow up. The majority of patients were diagnosed via kidney biopsy and underwent partial nephrectomy.
The authors concluded that BMO is associated with chronic kidney disease and slower tumor growth. The authors also concluded that BMO can be diagnosed using kidney biopsy, and given its slower growth may be managed by active surveillance. Chronic kidney disease is important to consider in patients with sporadic bilateral multifocal oncocytoma. It would be interesting to perform the study in a larger sample to see if the decrease in renal function will progress in patients with this pathology.
Presented by Daniel Su, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA
National Cancer Institute, Bethesda, MD USA
Written by Garen Abedi, MD, University of California (Irvine), and medical writer for UroToday.com